Logo image of BON

BON NATURAL LIFE LTD-A (BON) Stock Fundamental Analysis

NASDAQ:BON - Nasdaq - KYG144921213 - Common Stock - Currency: USD

0.066  -0.01 (-8.97%)

After market: 0.0656 0 (-0.61%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BON. BON was compared to 85 industry peers in the Chemicals industry. The financial health of BON is average, but there are quite some concerns on its profitability. BON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BON had positive earnings in the past year.
BON had a negative operating cash flow in the past year.
Each year in the past 5 years BON has been profitable.
In multiple years BON reported negative operating cash flow during the last 5 years.
BON Yearly Net Income VS EBIT VS OCF VS FCFBON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

BON has a Return On Assets (0.64%) which is comparable to the rest of the industry.
BON has a Return On Equity (0.91%) which is comparable to the rest of the industry.
The Return On Invested Capital of BON (2.44%) is worse than 65.88% of its industry peers.
BON had an Average Return On Invested Capital over the past 3 years of 8.52%. This is in line with the industry average of 7.10%.
The 3 year average ROIC (8.52%) for BON is well above the current ROIC(2.44%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.64%
ROE 0.91%
ROIC 2.44%
ROA(3y)9.09%
ROA(5y)10.38%
ROE(3y)11.65%
ROE(5y)16.28%
ROIC(3y)8.52%
ROIC(5y)10.57%
BON Yearly ROA, ROE, ROICBON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

The Profit Margin of BON (1.67%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of BON has declined.
The Operating Margin of BON (7.86%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of BON has declined.
The Gross Margin of BON (29.82%) is comparable to the rest of the industry.
BON's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 7.86%
PM (TTM) 1.67%
GM 29.82%
OM growth 3Y-28.15%
OM growth 5Y-16.51%
PM growth 3Y-54.74%
PM growth 5Y-36.12%
GM growth 3Y2.25%
GM growth 5Y-1.53%
BON Yearly Profit, Operating, Gross MarginsBON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 10 20 30

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BON is creating value.
BON has more shares outstanding than it did 1 year ago.
BON has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BON is higher compared to a year ago.
BON Yearly Shares OutstandingBON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BON Yearly Total Debt VS Total AssetsBON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 1.44, we must say that BON is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.44, BON is not doing good in the industry: 61.18% of the companies in the same industry are doing better.
BON has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BON (0.15) is better than 82.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 1.44
ROIC/WACC0.58
WACC4.2%
BON Yearly LT Debt VS Equity VS FCFBON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

BON has a Current Ratio of 2.42. This indicates that BON is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.42, BON is doing good in the industry, outperforming 69.41% of the companies in the same industry.
BON has a Quick Ratio of 2.32. This indicates that BON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.32, BON belongs to the best of the industry, outperforming 87.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.32
BON Yearly Current Assets VS Current LiabilitesBON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

BON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.73%.
Measured over the past years, BON shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.23% on average per year.
The Revenue for BON has decreased by -19.23% in the past year. This is quite bad
Measured over the past years, BON shows a small growth in Revenue. The Revenue has been growing by 7.78% on average per year.
EPS 1Y (TTM)-97.73%
EPS 3Y-70.62%
EPS 5Y-44.23%
EPS Q2Q%-95.37%
Revenue 1Y (TTM)-19.23%
Revenue growth 3Y-2.21%
Revenue growth 5Y7.78%
Sales Q2Q%-11.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
BON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.08% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year77.63%
Revenue Next 2Y45.28%
Revenue Next 3Y34.64%
Revenue Next 5Y24.08%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BON Yearly Revenue VS EstimatesBON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
BON Yearly EPS VS EstimatesBON Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2 4 6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 0.60 indicates a rather cheap valuation of BON.
Based on the Price/Earnings ratio, BON is valued cheaper than 98.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of BON to the average of the S&P500 Index (28.88), we can say BON is valued rather cheaply.
Industry RankSector Rank
PE 0.6
Fwd PE N/A
BON Price Earnings VS Forward Price EarningsBON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

98.82% of the companies in the same industry are more expensive than BON, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.55
BON Per share dataBON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BON NATURAL LIFE LTD-A

NASDAQ:BON (4/30/2025, 8:00:01 PM)

After market: 0.0656 0 (-0.61%)

0.066

-0.01 (-8.97%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)12-06 2024-12-06
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners48.11%
Ins Owner ChangeN/A
Market Cap275.22K
Analysts0
Price TargetN/A
Short Float %34.88%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.6
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA 0.55
EPS(TTM)0.11
EY166.67%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS5.72
BVpS10.53
TBVpS10.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.64%
ROE 0.91%
ROCE 4.13%
ROIC 2.44%
ROICexc 2.44%
ROICexgc 2.48%
OM 7.86%
PM (TTM) 1.67%
GM 29.82%
FCFM N/A
ROA(3y)9.09%
ROA(5y)10.38%
ROE(3y)11.65%
ROE(5y)16.28%
ROIC(3y)8.52%
ROIC(5y)10.57%
ROICexc(3y)8.65%
ROICexc(5y)11.01%
ROICexgc(3y)8.8%
ROICexgc(5y)11.18%
ROCE(3y)13.84%
ROCE(5y)17.18%
ROICexcg growth 3Y-44.37%
ROICexcg growth 5Y-33.89%
ROICexc growth 3Y-44.35%
ROICexc growth 5Y-33.92%
OM growth 3Y-28.15%
OM growth 5Y-16.51%
PM growth 3Y-54.74%
PM growth 5Y-36.12%
GM growth 3Y2.25%
GM growth 5Y-1.53%
F-Score2
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA 2.24
Cap/Depr 0.64%
Cap/Sales 0.03%
Interest Coverage 6.18
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.32
Altman-Z 1.44
F-Score2
WACC4.2%
ROIC/WACC0.58
Cap/Depr(3y)764.29%
Cap/Depr(5y)1250.29%
Cap/Sales(3y)6.63%
Cap/Sales(5y)12.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.73%
EPS 3Y-70.62%
EPS 5Y-44.23%
EPS Q2Q%-95.37%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.23%
Revenue growth 3Y-2.21%
Revenue growth 5Y7.78%
Sales Q2Q%-11.13%
Revenue Next Year77.63%
Revenue Next 2Y45.28%
Revenue Next 3Y34.64%
Revenue Next 5Y24.08%
EBIT growth 1Y-68.34%
EBIT growth 3Y-29.74%
EBIT growth 5Y-10.01%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-319.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1084.66%
OCF growth 3YN/A
OCF growth 5YN/A